Dan Lipsker

Dan Lipsker

Auto-generated profile, based on publicly available information

Dan Lipsker

Faculty of Medicine Strasbourg University Strasbourg France

Research Focus & Metrics

Academic Career Length

34Years (1993-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 March 2013 in Allergy
Verified
Journal Article
Open access
PDF file
ASA. Simon
A. Simon
BAB. Asli
B. Asli
MBM. Braun‐Falco
M. Braun‐Falco
HKH. De Koning
H. De Koning
JFJ.‐P. Fermand
J.‐P. Fermand
DLD. Lipsker
D. Lipsker
Schnitzler's syndrome is characterized by recurrent urticarial rash and monoclonal gammopathy, associated with clinical and biological signs of inflammation and a long‐term risk of AA amyloidosis and overt lymphoproliferation. An extensive literature review was performed, and the following questions were addressed during an expert meeting: In whom should Schnitzler's syndrome be suspected? How should the diagnosis of Schnitzler's syndrome be established? How should a patient with Schnitzler's syndrome be treated? How should a patient with Schnitzler's syndrome be followed up?. A diagnosis of Schnitzler's syndrome is considered definite in any patient with two obligate criteria: a recurrent urticarial rash and a monoclonal IgM gammopathy, and two of the following minor criteria: recurrent fever, objective signs of abnormal bone remodeling, elevated CRP level or leukocytosis, and a neutrophilic infiltrate on skin biopsy. It is considered probable, if only 1 minor criterion is present. In patients with monoclonal IgG gammopathies, diagnosis is definite if three minor criteria are present and possible if two are present. First‐line treatment in patients with significant alteration of quality of life or persistent elevation of markers of inflammation should be anakinra. Follow‐up should include clinical evaluation, CBC and CRP every 3 months and MGUS as usually recommended.

8 August 2016 in Journal of the European Academy of Dermatology and Venereology
Verified
Journal Article
Closed access
PDF file
DLD. Lipsker
D. Lipsker

26 August 2016 in Allergy
Verified
Journal Article
Open access
PDF file
LGL. Gusdorf
L. Gusdorf
BAB. Asli
B. Asli
SBSebastien Barbarot
Sebastien Barbarot
ANA. Néel
A. Néel
AMA. Masseau
A. Masseau
DLD. Lipsker
D. Lipsker
Background Schnitzler syndrome is characterized by an urticarial rash, a monoclonal gammopathy, and clinical, histological, and biological signs of neutrophil‐mediated inflammation. The aim of this study was to assess the applicability and validity of the existing diagnostic criteria in real‐life patients. Methods This multicentric study was conducted between 2009 and 2014 in 14 hospitals in which patients with Schnitzler syndrome or controls with related disorders were followed up. We compared the sensitivities and specificities and calculated the positive and negative predictive values of the Lipsker and of the Strasbourg criteria for the patients with Schnitzler syndrome and for the controls. We included 42 patients with Schnitzler syndrome, 12 with adult‐onset Still's disease, 7 with cryopyrin‐associated periodic disease, 9 with Waldenström disease, and 10 with chronic spontaneous urticaria. Results All patients with Schnitzler syndrome met the Lipsker criteria. According to the Strasbourg criteria, 34 patients had definite Schnitzler syndrome, five had probable Schnitzler syndrome, and three did not meet the criteria. One control met the Lipsker criteria and had probable Schnitzler syndrome according to the Strasbourg criteria. Sensitivity and specificity of the Lipsker criteria were 100% and 97%, respectively. For the Strasbourg criteria, sensitivity for definite and probable diagnosis was 81% and 93%, respectively, with a corresponding specificity of 100% and 97%. Conclusion Diagnostic criteria currently in use to diagnose Schnitzler syndrome are reliable. More investigations must be done to attest their efficiency in patients with recent‐onset manifestations.

17 July 2017 in Current Rheumatology Reports
Verified
Journal Article
Closed access
PDF file
LGL. Gusdorf
L. Gusdorf
DLD. Lipsker
D. Lipsker

19 February 2016 in Dermatology
Verified
Journal Article
Open access
PDF file
DLDan Lipsker
Dan Lipsker
FSFrançois Severac
François Severac
MFMarie Freysz
Marie Freysz
ESErik A Sauleau
Erik A Sauleau
JBJurr Boer
Jurr Boer
GJGregor B.E. Jemec
Gregor B.E. Jemec
Background: The precise clinical description of skin lesions observed in some patients with hidradenitis suppurativa (HS) can be extremely difficult. Objective: Establishing a validated glossary of terms allowing the best possible description of lesions observed in HS patients. Material and Methods: Five international experts of HS were to assess a series of 25 photos representing typical lesions of this disorder. For each photo, the experts were asked whether naming of the lesions was possible or not and, if yes, by using which noun. Agreement of their responses was calculated using Fleiss's kappa index. Using a Delphi strategy, photos with disagreement were discussed, and photos were reevaluated on the next day. In case of agreement on the impossibility of naming some clinical situations, new terms, to be included into the glossary, were agreed upon. Results: After the first round of photos, agreement between the experts was poor with a kappa index of only 0.33 (95% CI 0.22-0.46). After extensive discussion of cases with disagreement, the kappa index increased on day 2 to 0.75 (95% CI 0.60-0.87), allowing to conclude on good interobserver agreement on terminology. Furthermore, a few clinical situations were identified in which naming with established semantics is so far not possible. For these situations, the terms ‘multicord', ‘multipore', ‘multitunnel' and ‘retraction' were defined. Discussion: This is the first validation of clinical terms used to describe lesions in patients with HS. This should be helpful in better defining the clinical phenotypes observed in this disorder.

1 January 2012 in Archives of Dermatology
Verified
Journal Article
Open access
PDF file
VLVirginie Lutz
Virginie Lutz
CÈCamille Franc Ès
Camille Franc Ès
DBDidier Bessis
Didier Bessis
ACAnne Cosnes
Anne Cosnes
NKNicolas Kluger
Nicolas Kluger
DLDan Lipsker
Dan Lipsker
Morphea and lichen sclerosus (LS) are 2 entities that are characterized clinically by plaques of indurated, sclerotic, and dyschromic skin and pathologically by an inflammatory dermal infiltrate and dermal fibrosis. Their cause is largely unknown, although both genetic factors, such as predisposing HLA alleles, and environmental factors, such as infection with Borrelia burgdorferi, have been involved in some cases.1-15 Autoimmune diseases and/or stigmata are more frequent in patients with morphea or LS than in unaffected persons.1,16-20